File photo of Russian single-dose vaccine against Sputnik Light Coronavirus (Photo credit: Russian Direct Investment Fund via Reuters)
The Russia-made Sputnik V coronavirus vaccine will only be available in select private hospitals, said Deepak Sapra, CEO (API and Services) of Dr. Reddy’s Laboratories. The Hyderabad-based pharmaceutical company has partnered with the Russian Direct Investment Fund (RDIF) to bring the two-dose adenoviral vaccine to India.
For the first few days, Sputnik V will only be available in selected private hospitals in the country, as the shock has to be stored at -18 degrees Celsius.
Dr. Reddy’s is also working on the data needed to apply for regulatory approval for the Single-dose vaccine against Sputnik Light.
Clinical trials are being conducted with Sputnik Light in Russia, and the same ones for Sputnik V have already been conducted in India, Sapra said. “I hope that once Sputnik Light is brought to India, it will be a shot in the arm for the country’s vaccination program. The most important part is that a single-dose vaccine instead of two doses can give 80 percent effectiveness,” added he added.
What is #SputnikV Light? Deepak Sapra, API and Services, explains Dr. Reddy’s lab.
((nesnehamordani ) #ITVideo pic.twitter.com/1uj95fQqyF
– IndiaToday (@IndiaToday) May 14, 2021
NITI Aayog Member (Health) Dr. VK Paul said at a press conference earlier this month, “In the case of Sputnik Light, they did [RDIF] say the first dose is enough. We test this claim; We’ll go over its dates and immunogenicity and after that we’ll see. Let in more information. “
“Expect more deliveries from Sputnik V by mid-June”
Sputnik V that was granted Emergency approval by DCGI In April of this year, a few weeks after the supply and storage chain has been set up, state vaccination centers will be supplied, Sapra told India Today TV.
“Sputnik V was administered to the first Indians on Friday,” he said.
We are currently working with private hospitals and we are also working very closely with the government: Deepak Sapra, API and Services, Dr. Reddy’s labs. nesnehamordani #ITVideo pic.twitter.com/cbze6tifqk
– IndiaToday (@IndiaToday) May 14, 2021
Deepak Sapra, CEO (API and Services) from Dr. Reddys Laboratories said there are currently a total of 1.50,000 doses of Sputnik V vaccine in India. The company expects further shipments from Russia later this month and in June, he added.
Sputnik V will appear on CoWin: Deepak Sapra
A Pilot batch of 1.5 lakh cans of the Russian vaccine arrived in Hyderabad on May 1st. A batch of samples was then sent to the Central Drugs Laboratory in Kasauli for regulatory approval. The release didn’t take much time, Sapra said, adding that regulators need to do a careful review before approving the vaccine.
When asked how the launch will affect vaccination in India, Sapra said eligible recipients will soon see three vaccines instead of two in the CoWin app.
“Will be affordable once production starts in India”
The price of the Sputnik V vaccine that is is sold at Rs 995 per dose They are currently being reduced once Indian companies start manufacturing, said Deepak Sapra, CEO (API and Services) of Dr. Reddy’s Laboratories.
As of October, up to 20 million doses of the Russian Covid-19 vaccine can be made every month, he adds.
Deepak Sapra, API and Services, Dr. Reddy’s labs talk about the issue of clearance, the prices of vaccines, and things that are being done to get people the vaccine. look here
nesnehamordani#ITVideo pic.twitter.com/Jcf1ZermXv– IndiaToday (@IndiaToday) May 14, 2021
“Currently the vaccine is imported from Russia and we are distributing it through cold chain building and logistics. Therefore the price is Rs 948 + GST. If we produce it in India we expect economies of scale will allow us to make it more affordable and accessible “said Sapra.
He also said efforts are being made to keep the vaccine between 2 and 8 degrees Celsius.
2-DG will be cheaper than alternatives: Sapra
In relation to DRDO’s coronavirus drug 2-DGDeepak Sapra by Dr. Reddys Laboratories said it was much cheaper than tocilizumab and other alternatives used in treating Covid-19 patients in India.
The DRDO in collaboration with Dr. The drug developed by Reddy’s Laboratories has been shown to reduce the reliance of Covid-19 patients on medical oxygen and improve recovery time.
“The drug that will be Available in sachets and can be taken orallyhas shown that oxygen saturation levels improve, “said Deepak Sapra, CEO (API and Services) of Dr. Reddy’s Laboratories.
एक टिप्पणी भेजें